Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC122505MsOH Tablets in Healthy Adult Subjects

Phase 1

Completed

• Conditions: Parkinson Disease
• Interventions: Drug: HEC122505MsOH

• Registration Number: NCT04625361
• Lead Sponsor: Sunshine Lake Pharma Co., Ltd.

Brief Summary

The Safety, Tolerability, Pharmacokinetic and Food Effect Study of HEC122505MsOH Tablets in Healthy Subjects

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-11-09
• Study First Submitted QC: 2020-11-09
• Study First Posted: 2020-11-12
• Study Start: 2021-01-20
• Primary Completion: 2022-01-06
• Study Completion: 2022-01-06
• Status Verified: 2023-04
• Last Update Submitted: 2023-04-12
• Last Update Posted: 2023-04-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 106

Inclusion Criteria

1. Subjects who are willing and are able to provide a written informed consent to participate in the study.
2. Without Plann for pregnancy or pregnant within 3 months after enrollment throughout the trial.
3. Subjects aged between 18 and 45 (both inclusive) years old.
4. Healthy volunteers has a body weight ≥50 kg (for male) or ≥ 45kg (for female) and body mass index ≥18 and ≤28 kg/m2 at screening.
5. Subjects, who are healthy, as having no clinically significant abnormalities in vital signs, physical examination, clinical laboratory test results, Chest X-ray and 12-lead electrocardiogram (ECG).

Exclusion Criteria

1. Subjects with a positive serology for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies and/or TP antibodies at screening.
2. Patients with the following diseases of clinical significance, including but not limited to those with gastrointestinal, kidney, liver, nerve, blood, endocrine, tumor, lung, immune, mental, or cardiovascular and cerebrovascular diseases.
3. nown allergic reactions or hypersensitivity to any excipient of the drug formulation(s)， anaphylaxis physique.
4. Use of any prescription or non-prescription medications within 14 days prior to initial dosing，Use of any drugs that inhibit or induce liver metabolism within 28 days before the first dose, or use of any of the following drugs within 28 days before the first dose: monoamine oxidase inhibitors, opioids, serotonergic drugs, sympathetic nerves Drugs, breast cancer resistance protein substrates, dopaminergic antagonists, etc.
5. Consume foods or beverages containing caffeine, xanthine, alcohol, and grapefruit within 48 hours prior to initial dosing.
6. Positive results from urine drug screen test.
7. History of alcoholism or drink regularly within 3 months prior to the study (defined as Alcohol consumption of > 21 units/week), or positive results from alcohol breath test.
8. Regular smoking of more than 10 cigarettes per day within 3 months before administration of study drug, or inability to refrain from smoking during the course of the study.
9. Donate blood or lose blood 400 mL or more within 1 month prior to initial dosing.
10. Subjects who plan to receive or have had organ transplants.
11. Females who are lactating/breastfeeding, or positive result from pregnancy test for women of child-bearing potential.
12. Subjects who participated in another clinical trial within 3 months prior to initial dosing.
13. Any other condition with in the opinion of the investigator would render the patient unsuitable for inclusion in the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Single dose of HEC122505MsOH Tablets（Part 1， Cohort 1）	HEC122505MsOH	Healthy subjects receive single dose of HEC122505MsOH or matching placebo
Single dose of HEC122505MsOH Tablets（pilot trial arm）	HEC122505MsOH	Healthy subjects receive single dose of tablets HEC122505MsOH
Single dose of HEC122505MsOH Tablets（Part 1，Cohort 5）	HEC122505MsOH	Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
Single dose of HEC122505MsOH Tablets（Part 1， Cohort 2）	HEC122505MsOH	Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 1）	HEC122505MsOH	Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
Single dose of HEC122505MsOH Tablets（Part 1， Cohort 4）	HEC122505MsOH	Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
Single dose of HEC122505MsOH Tablets（Part 1， Cohort 6）	HEC122505MsOH	Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
Single dose of HEC122505MsOH Tablets（Part 1， Cohort 3,Fed/Fasting）	HEC122505MsOH	Following an overnight fast of at least 10 hours, a single dose of HEC585 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 3）	HEC122505MsOH	Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 2）	HEC122505MsOH	Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo

Primary Outcome Measures

Name	Time	Method
The Number of Adverse Events (AEs)	Part 1：up to 6 days; Part 2: up to 13 days.	To investigate the safety and tolerability of HEC122505MsOH by assessment of AEs (non-serious and serious) following administration of oral HEC122505MsOH tablets

Secondary Outcome Measures

Name	Time	Method
Cmax	up to 120 hours	Maximum Plasma Concentration(Cmax)
Tmax Tmax	up to 120 hours	Maximum Peak Time(Tmax)
t½	up to 120 hours	Elimination Half-life(t½)
AUC	up to 120 hours	Area Under the Curve(AUC)
CL/F	up to 120 hours	Apparent Clearance(CL/F)
Kel	up to 120 hours	Elimination Rate Constant(Kel)
MRT	up to 120 hours	Mean Residence Time(MRT)
Vz/F	up to 120 hours	Apparent Volume of Distribution(Vz/F)

Trial Locations

Locations (1)

Shanghai Xuhui Central Hospital; 🇨🇳 Shanghai, China